Luis Baez Vallecillo, MD
Hematology & Oncology · San Juan, PRNPI 1265788855
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.9%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 48 manufacturers reported payments, led by Lilly USA, LLC at 27.5% of the total. Reporting peaked in 2024 at $27,730 and has fallen 67.2% since, to $9,086 in 2025. Among hematology & oncology clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,112 payments — averaging $95.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$29K
- Merck$23K
- E.r. Squibb & Sons, L.L.C.$16K
- AstraZeneca$11K
- Eli Lilly Export S.A. Puerto Rico Branch$8K
- Novartis$4K
- plus $14K from 42 others
Across 5 payments — averaging $48,655 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$213K
- Pfizer$30K
What the payments were for
- Consulting fees$27,18726%
- Speaking & faculty fees$54,24651%
- Food & beverage$22,50621%
- Education$1,3701%
- Other$1,2801%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$106,589 in reported general payments places this provider in the 95th percentile of 138 hematology & oncology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 225 | $3,602,269 |
| VerzenioAbemaciclib | 132 | $2,053,329 |
| ErleadaApalutamide | 72 | $1,099,862 |
| KisqaliRibociclib Succinate | 50 | $705,235 |
| TagrissoOsimertinib Mesylate | 27 | $447,108 |
| TukysaTucatinib | 15 | $391,907 |
| CabometyxCabozantinib S-Malate | 11 | $278,619 |
| BosulifBosutinib | 14 | $273,916 |
| AlecensaAlectinib Hcl | 13 | $236,185 |
| XtandiEnzalutamide | 11 | $159,400 |
| LibtayoCemiplimab-Rwlc | 15 | $154,803 |
| LonsurfTrifluridine/Tipiracil Hcl | 12 | $115,125 |
| FulphilaPegfilgrastim-Jmdb | 49 | $103,452 |
| TykerbLapatinib Ditosylate | 12 | $65,892 |
| XgevaDenosumab | 18 | $58,481 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Bosulif, Eliquis | $267 | $3,890,999262 claims |
| Lilly USA, LLCVerzenio | $29,323 | $2,053,329132 claims |
| Johnson & JohnsonErleada, Xarelto | $1,973 | $1,116,94598 claims |
| NovartisKisqali | $4,076 | $705,23550 claims |
| AstraZenecaTagrisso | $11,498 | $447,10827 claims |
| Seagen Inc.Tukysa | $272 | $391,90715 claims |
| Exelixis Inc.Cabometyx | $105 | $278,61911 claims |
| Genentech USA, Inc.Alecensa | $1,006 | $236,18513 claims |
| Astellas Pharma US IncXtandi | $225 | $159,40011 claims |
| Regeneron Healthcare Solutions, Inc.Libtayo | $155 | $154,80315 claims |
| Taiho Oncology, Inc.Lonsurf | $255 | $115,12512 claims |
| AmgenXgeva, Prolia | $1,349 | $86,36134 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 138 hematology & oncology providers in Puerto Rico.
Other hematology & oncology in San Juan
- Alexis Cruz ChaconSan Juan$450K
- Jose Lozada CostasSan Juan$260K
- Cristian Rodriguez ArochoSan Juan$227K
- Noridza Rivera RodriguezSan Juan$177K
- Mirelis AcostaSan Juan$154K
- Edgardo Santiago-GuzmanSan Juan$79K
- Adelba Torres-LopezSan Juan$73K
- Karla Feliciano SalvaSan Juan$44K
- Luis Delgado MateuSan Juan$39K
- Sixto PerezSan Juan$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.